Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. (Q39469395)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21941364%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21941364%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21941364%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Aaron Schimmer

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21941364%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

7

S Zweegman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21941364%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

N E Franke

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21941364%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

D Niewerth

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21941364%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Y G Assaraf

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21941364%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

J van Meerloo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21941364%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

K Vojtekova

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21941364%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

C H van Zantwijk

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21941364%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

E T Chan

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21941364%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

C J Kirk

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21941364%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

G J L Kaspers

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21941364%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

G Jansen

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21941364%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

J Cloos

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21941364%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

23 September 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21941364%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21941364%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21941364%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21941364%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

757-768

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21941364%20AND%20SRC:MED&resulttype=core&format=json

The 26 S proteasome: from basic mechanisms to drug targeting

13 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Subunit of the '20S' proteasome (multicatalytic proteinase) encoded by the major histocompatibility complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Regulation of proteasome complexes by gamma-interferon and phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Novel proteasome inhibitors to overcome bortezomib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Proteasome inhibition as novel treatment strategy in leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Proteasome inhibitors in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Proteasome inhibitors in cancer therapy: lessons from the first decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Mechanisms of proteasome inhibitor action and resistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

The structure of the mammalian 20S proteasome at 2.75 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Effect of noncompetitive proteasome inhibition on bortezomib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Characterization of the proteasome using native gel electrophoresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Structure of 20S proteasome from yeast at 2.4 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

20S proteasome and its inhibitors: crystallographic knowledge for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Resistance to imatinib: mutations and beyond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

DNA topoisomerase II mutations and resistance to anti-tumor drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Drug resistance caused by reversion mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Differences in reversion of resistance mutations to wild-type under structured treatment interruption and related increase in replication capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

Cells adapted to the proteasome inhibitor 4-hydroxy- 5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

inferred from DOI database lookup

7 January 2021

based on heuristic

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.256

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2011.256

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21941364%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference